Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity

Yang Wang(Hangzhou Wanxiang Polytechnic), Yuhong Zhou(Sun Yat-sen University)
Antibody Therapeutics
June 24, 2024
Cited by 11


Related Papers